Predictions of time to HIV viral rebound following ART suspension that incorporate personal biomarkers
暂无分享,去创建一个
[1] A. Perelson,et al. Modeling the Effects of Vorinostat In Vivo Reveals both Transient and Delayed HIV Transcriptional Activation and Minimal Killing of Latently Infected Cells , 2015, PLoS pathogens.
[2] C. Fletcher,et al. A Antiretroviral Drug Penetration into Lymphoid Tissue , 2015 .
[3] K. Tashima,et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] S. Lewin,et al. Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5–8 Days , 2016, PLoS pathogens.
[5] A. Perelson,et al. Probabilistic control of HIV latency and transactivation by the Tat gene circuit , 2018, Proceedings of the National Academy of Sciences.
[6] D. Douek. HIV Infection: Advances Toward a Cure. , 2018, Topics in antiviral medicine.
[7] R. Lempicki,et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[8] Sarah B. Laskey,et al. Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure , 2013, Cell.
[9] M. Lederman,et al. HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers , 2018, The Journal of clinical investigation.
[10] Alan S. Perelson,et al. Determination of virus burst size in vivo using a single-cycle SIV in rhesus macaques , 2007, Proceedings of the National Academy of Sciences.
[11] D. Richman,et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. , 2013, The New England journal of medicine.
[12] S. Hughes,et al. Clonally expanded CD4+ T cells can produce infectious HIV-1 in vivo , 2016, Proceedings of the National Academy of Sciences.
[13] Martin A. Nowak,et al. Antiretroviral dynamics determines HIV evolution and predicts therapy outcome , 2012, Nature Medicine.
[14] Nancie M Archin,et al. Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies. , 2015, The Journal of infectious diseases.
[15] Igor M. Rouzine,et al. A Hardwired HIV Latency Program , 2015, Cell.
[16] R. Siliciano,et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells , 2003, Nature Medicine.
[17] Daniel I. S. Rosenbloom,et al. Corrections: Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1 (Proc Natl Acad Sci USA (2014) 111, (13475-13480) doi: 10.1073/pnas.1406663111) , 2014 .
[18] Eric J. Arts,et al. Changes in Human Immunodeficiency Virus Type 1 Fitness and Genetic Diversity during Disease Progression , 2005, Journal of Virology.
[19] Daniel Coombs,et al. Stochastic Analysis of Pre- and Postexposure Prophylaxis against HIV Infection , 2013, SIAM J. Appl. Math..
[20] B. Walker,et al. The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies , 2018, The Journal of infectious diseases.
[21] J. Lawrence,et al. A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024). , 2006, The Journal of infectious diseases.
[22] Feng Fu,et al. Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1 , 2014, Proceedings of the National Academy of Sciences.
[23] Alan S. Perelson,et al. Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.
[24] Brigitte Autran,et al. Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study , 2013, PLoS pathogens.
[25] M. Carrington,et al. HIV-1 DNA predicts disease progression and post-treatment virological control , 2014, eLife.
[26] David R. Anderson,et al. Model selection and multimodel inference : a practical information-theoretic approach , 2003 .
[27] B. Berkhout,et al. What do we measure when we measure cell-associated HIV RNA , 2018, Retrovirology.
[28] F. Mentré,et al. Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action , 2010, Clinical pharmacokinetics.
[29] Alan S. Perelson,et al. Early HIV Infection Predictions: Role of Viral Replication Errors , 2018, SIAM J. Appl. Math..
[30] J. Blankson. Effector mechanisms in HIV-1 infected elite controllers: highly active immune responses? , 2010, Antiviral research.
[31] D. Richman,et al. Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: Intrinsic stability predicts lifelong persistence , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[32] Alan S. Perelson,et al. A Novel Antiviral Intervention Results in More Accurate Assessment of Human Immunodeficiency Virus Type 1 Replication Dynamics and T-Cell Decay In Vivo , 2003, Journal of Virology.
[33] Jessica M Conway,et al. Post-treatment control of HIV infection , 2015, Proceedings of the National Academy of Sciences.
[34] J. Lifson,et al. Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy , 2017, PLoS pathogens.
[35] G. Gao,et al. PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors. , 2007, Blood.
[36] K. P. Murphy,et al. Janeway's immunobiology , 2007 .
[37] M. Lederman,et al. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption , 2015, AIDS.
[38] Daniel I. S. Rosenbloom,et al. Insufficient Evidence for Rare Activation of Latent HIV in the Absence of Reservoir-Reducing Interventions , 2016, PLoS pathogens.
[39] Alan S. Perelson,et al. Stochastic Theory of Early Viral Infection: Continuous versus Burst Production of Virions , 2011, PLoS Comput. Biol..
[40] Sebastian Bonhoeffer,et al. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis , 1999, The Lancet.
[41] R. D. de Boer,et al. Do Most Lymphocytes in Humans Really Reside in the Gut? , 2022 .
[42] Alan S. Perelson,et al. Residual Viremia in Treated HIV+ Individuals , 2016, PLoS Comput. Biol..
[43] C. Rouzioux,et al. Hiv-1 Control after Transient Antiretroviral Treatment Initiated in Primary Infection: Role of Patient Characteristics and Effect of Therapy , 2012, Antiviral therapy.
[44] Hartmut Derendorf,et al. Modeling of Pharmacokinetic/Pharmacodynamic (PK/PD) Relationships: Concepts and Perspectives , 1999, Pharmaceutical Research.
[45] A. Haase,et al. Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption , 2015, Proceedings of the National Academy of Sciences.
[46] J. Mellors,et al. The need for treatment interruption studies and biomarker identification in the search for an HIV cure. , 2015, AIDS.
[47] Geneviève Boucher,et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation , 2009, Nature Medicine.
[48] R. Siliciano,et al. Recent developments in the search for a cure for HIV-1 infection: targeting the latent reservoir for HIV-1. , 2014, The Journal of allergy and clinical immunology.
[49] V. Johnson,et al. Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068. , 2006, The Journal of infectious diseases.
[50] C. Rouzioux,et al. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[51] R. Siliciano,et al. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations , 2015, Nature.
[52] J. Shuter. Forgiveness of non-adherence to HIV-1 antiretroviral therapy. , 2008, The Journal of antimicrobial chemotherapy.
[53] Emily B Hanhauser,et al. Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV , 2016, PLoS pathogens.
[54] Ruy M Ribeiro,et al. Modeling the within-host dynamics of HIV infection , 2013, BMC Biology.
[55] Alan S Perelson,et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues , 2014, Proceedings of the National Academy of Sciences.
[56] Alan S. Perelson,et al. Mathematical Analysis of HIV-1 Dynamics in Vivo , 1999, SIAM Rev..
[57] Matthew C Strain,et al. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. , 2005, The Journal of infectious diseases.
[58] A S Perelson,et al. Modeling plasma virus concentration during primary HIV infection. , 2000, Journal of theoretical biology.
[59] M. Carrington,et al. Relationship of HIV reservoir characteristics with immune status and viral rebound kinetics in an HIV therapeutic vaccine study , 2014, AIDS.
[60] A. Perelson,et al. HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.
[61] E. Rosenberg,et al. Safety and Immunogenicity of Therapeutic DNA Vaccination in Individuals Treated with Antiretroviral Therapy during Acute/Early HIV-1 Infection , 2010, PLoS ONE.
[62] R. Schooley,et al. AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein. , 2010, The Journal of infectious diseases.
[63] Sebastian Bonhoeffer,et al. Decelerating Decay of Latently Infected Cells during Prolonged Therapy for Human Immunodeficiency Virus Type 1 Infection , 2002, Journal of Virology.
[64] Daniel Coombs,et al. A Stochastic Model of Latently Infected Cell Reactivation and Viral Blip Generation in Treated HIV Patients , 2011, PLoS Comput. Biol..
[65] M. Proschan,et al. A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection , 2017, Science Translational Medicine.
[66] Lin Shen,et al. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs , 2008, Nature Medicine.
[67] Libin Rong,et al. Modeling HIV persistence, the latent reservoir, and viral blips. , 2009, Journal of theoretical biology.
[68] M. Hirsch,et al. Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment , 2009, AIDS.
[69] P. Goulder,et al. Post-treatment control or treated controllers? Viral remission in treated and untreated primary HIV infection , 2017, AIDS.
[70] M. Lederman,et al. Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy , 2015, Journal of Virology.
[71] A. Perelson. Modelling viral and immune system dynamics , 2002, Nature Reviews Immunology.
[72] H. T. Banksa,et al. Estimation and Prediction With HIV-Treatment Interruption Data , 2007 .
[73] D. Freedman,et al. Multistage models for carcinogenesis. , 1989, Environmental health perspectives.
[74] C. Boucher,et al. Unite forces to validate biomarkers in the quest for lasting HIV remission. , 2016, AIDS.
[75] D. Havlir,et al. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. , 2007, The Journal of infectious diseases.
[76] Taina T. Immonen,et al. Principles Governing Establishment versus Collapse of HIV-1 Cellular Spread. , 2019, Cell host & microbe.
[77] S. Hughes,et al. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells , 2014, Science.
[78] M. L. Simpson,et al. Transcriptional bursting from the HIV-1 promoter is a significant source of stochastic noise in HIV-1 gene expression. , 2010, Biophysical journal.
[79] R. Phillips,et al. Immunological biomarkers predict HIV-1 viral rebound after treatment interruption , 2015, Nature Communications.
[80] Simon Wain-Hobson. Virus Dynamics: Mathematical Principles of Immunology and Virology , 2001, Nature Medicine.
[81] R. Siliciano,et al. HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study , 2017, PLoS medicine.
[82] Anthony D. Kelleher,et al. HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission , 2015, PLoS pathogens.